| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation
to the consolidated net loss for the years ended December 31, 2025, and 2024 is included at the bottom of the table below.
| |
|
Twelve Months Ended
December 31, |
|
| Significant segment expenses |
|
2025 |
|
|
2024 |
|
| General and administrative (1) |
|
$ |
7,778,869 |
|
|
$ |
5,786,293 |
|
| Pre-clinical research |
|
|
378,343 |
|
|
|
1,479,896 |
|
| CMC |
|
|
1,887,466 |
|
|
|
1,463,530 |
|
| Clinical development (1) |
|
|
5,685,715 |
|
|
|
4,097,521 |
|
| Depreciation and amortization |
|
|
662,585 |
|
|
|
- |
|
| Share based compensation expense |
|
|
297,467 |
|
|
|
649,029 |
|
| Impairment expense |
|
|
4,162,911 |
|
|
|
- |
|
| Other segment items (2) |
|
|
3,939 |
|
|
|
773,693 |
|
| Total operating and segment expenses |
|
|
20,857,295 |
|
|
|
14,249,962 |
|
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
115,301 |
|
|
|
(77,806 |
) |
| Realized foreign currency translation loss from dissolution of subsidiaries |
|
|
(7,171 |
) |
|
|
- |
|
| Foreign currency gain/(loss) |
|
|
30,376 |
|
|
|
- |
|
| Other income |
|
|
380,532 |
|
|
|
- |
|
| Change in fair value of derivative warrant liability |
|
|
(416,619 |
) |
|
|
|
|
| Interest and dividends, net |
|
|
327,193 |
|
|
|
423,184 |
|
| Segment and consolidated net loss |
|
$ |
20,427,683 |
|
|
$ |
13,904,584 |
|
| (1) | includes personnel costs and excludes share-based compensation expense
and impairment expense |
| (2) | includes litigation settlements, loss from sale of assets, and loss on asset write offs |
|